# Intellia Therapeutics

Type: Company (NTLA)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/intellia-therapeutics
Canonical HTML page: https://gethealthbrief.com/entity/intellia-therapeutics

## Recent coverage (1 stories)

### Mid-Cap Biotech Earnings: Specialized Platforms Outperform in Q4 2025
2026-02-26 22:32:06 · Sentiment: Neutral · Impact: 5/10 · Sources: 12

The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Full story: https://gethealthbrief.com/story/mid-cap-biotech-q4-2025-earnings-intelligence

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.